{"schema_version":"1.0","type":"article","title":"When ADCs Enter Autoimmune Disease: Precision Immune Modulation, Not More Killing","url":"https://drugnews.com.tw/articles/2026-07-18-autoimmune-adc-lfd200-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-07-18-autoimmune-adc-lfd200-en.md","lang":"en","date":"2026-07-18","publish_at":"2026-07-18T20:00:00+08:00","updated_at":"2026-07-18","category":"商業分析系列","topic":"商業分析系列","tags":["Business Analysis","antibody-drug conjugates","autoimmune disease","LFD-200","Lifordi Immunotherapeutics","VISTA","glucocorticoid","immune modulation","rheumatoid arthritis","biotech investing"],"summary":"The opportunity for autoimmune ADCs is not to transplant oncology cytotoxins into immune cells. It is to deliver powerful glucocorticoids, small molecules, ASOs or siRNAs selectively to the cells that drive disease. LFD-200 offers an early human proof-of-mechanism signal for that thesis.","key_points":[],"facts":[],"sections":["01 | Autoimmune Treatment Is Moving From Suppressing Inflammation to Reshaping Immunity","02 | Two Paths for Autoimmune ADCs: Deplete the Cell or Modulate It","03 | LFD-200 Is the First Important Clinical Signal","04 | The Strategic Position: Between Biologics and Cell Therapy","05 | Autoimmune ADC Development Requires a New Rulebook","The Next Boundary for ADCs May Be Precision Immune Modulation","References"],"references":[{"title":"[Original Drugnews article on Dcard]","source":"","date":"","url":"https://www.dcard.tw/@drugnews/post/261839370"},{"title":"[Lifordi Immunotherapeutics: LFD-200 technology]","source":"","date":"","url":"https://www.lifordi.com/technology/lfd-200/"},{"title":"[Lifordi: preliminary phase 1 LFD-200 data presented at EULAR 2026]","source":"","date":"","url":"https://www.biospace.com/press-releases/lifordi-immunotherapeutics-presents-phase-1-clinical-data-for-lfd-200-a-subcutaneous-glucocorticoid-antibody-drug-conjugate-at-eular-2026"},{"title":"[ClinicalTrials.gov: NCT07207954]","source":"","date":"","url":"https://clinicaltrials.gov/study/NCT07207954"},{"title":"[Yaseen et al.: review of antibody-drug conjugates in autoimmune disease, PMID 40186891]","source":"","date":"","url":"https://pubmed.ncbi.nlm.nih.gov/40186891/"},{"title":"[Zhou et al.: review of ADC applications beyond oncology, PMID 40843358]","source":"","date":"","url":"https://pubmed.ncbi.nlm.nih.gov/40843358/"},{"title":"[CD19 CAR-T in autoimmune disease, Nature Medicine 2026]","source":"","date":"","url":"https://www.nature.com/articles/s41591-025-04185-6"},{"title":"[CD19 CAR-T case series in autoimmune disease, PMID 38381673]","source":"","date":"","url":"https://pubmed.ncbi.nlm.nih.gov/38381673/"}],"images":[{"alt":"The ADC platform moves from selective tumor killing toward selective immune modulation in autoimmune disease","url":"https://drugnews.com.tw/assets/articles/autoimmune-adc-lfd200-en/figure-01.webp"},{"alt":"Autoimmune ADCs follow two development paths: cell depletion and cell-selective immune modulation","url":"https://drugnews.com.tw/assets/articles/autoimmune-adc-lfd200-en/figure-02.webp"},{"alt":"LFD-200 targets VISTA-positive immune cells with eight glucocorticoid payloads and has produced an early human proof-of-mechanism signal","url":"https://drugnews.com.tw/assets/articles/autoimmune-adc-lfd200-en/figure-03.webp"},{"alt":"Autoimmune ADCs may occupy the strategic space between conventional biologics, small molecules and operationally intensive cell therapy","url":"https://drugnews.com.tw/assets/articles/autoimmune-adc-lfd200-en/figure-04.webp"}],"cover_image":"https://drugnews.com.tw/assets/articles/autoimmune-adc-lfd200-en/cover-1400.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-07-18）。When ADCs Enter Autoimmune Disease: Precision Immune Modulation, Not More Killing。https://drugnews.com.tw/articles/2026-07-18-autoimmune-adc-lfd200-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-07-18-autoimmune-adc-lfd200.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}